Loading clinical trials...

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma | Clinical Trials | Clareo Health

COMPLETEDNCT05673967

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Primary Objective: 1\. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRM...

Lead sponsor: Regeneron Pharmaceuticals•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment62

Start dateJan 2023

Last updatedApr 25, 2025

Condition

Relapsed and Refractory Multiple Myeloma (RRMM)

Locations shown

Regeneron Research Facility

Tarrytown, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 25, 2025Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions